Accessory parotid gland (APG) is salivary tissue that is anterior and anatomically separate from the parotid gland. Although the APG is a common anatomical variation, APG tumours are extremely rare. We report on 6 patients having APG tumours with emphasis on diagnosis, clinical features, indications and rationales for different treatment approaches.
INTRODUCTION
The evaluation of a mid-cheek mass represents a significant diagnostic and therapeutic challenge. Benign and malignant lesions in this area may arise from soft tissues of the face, including the skin, lymphatics, skin adnexa, neural, and salivary structures 1 .
The accessory parotid gland (APG) has been described as salivary tissue that is anterior and anatomically separate from the main body of the parotid gland and adjacent to Stensen's duct by way of one or multiple secondary connections. Frommer 2 , in his study of cadaveric dissections, found an APG in 21% of individuals, although some authors reported incidences as high as 56% 3 . Although the APG is a common anatomical variation, APG tumours are extremely rare, with a reported incidence of 1 to 7.7% of all parotid gland tumours, and a malignancy rate from 26 to 50% 4, 5 . So far, 157 lesions arising from accessory parotid gland have been reported in the English-language literature, including 54 malignant tumours, 80 benign tumours, and 23 nontumour lesions 6, 7 . There are few larger series describing APG tumours [4] [5] [6] [7] [8] [9] . To our knowledge, this is second largest European series regarding APG tumours. We report on 6 patients having APG tumours with emphasis on diagnosis and clinical features, as well as the indications and rationale for different treatment approaches. Table 1 .
There were three males and three females with a mean age of 39 years (range, 14-70). All patients except one had undergone no previous treatment. This latter patient is a 48-yearsold woman who received surgical treatment for a pleomorphic adenoma elsewhere (midcheek incision directly over the tumour) and has been referred to our Department because of local recurrence (Figure 1 ).
Three patients presented with a painless, progressively enlarging buccal mass, while two patients had painful lesions at the same location. One patient had painless mid-cheek lesion with numbness of the cheek and upper lip.
All patients had undergone FNAB preoperatively and the results were identical to those provided by patohistological analysis following operation. Histologically, of the 6 APG tumours, there were three pleomorphic adenomas (one of which was multilocular), one myoepithelioma, one adenoid cystic carcinoma and one high-grade mucoepidermoid carcinoma. Two patients with malignant disease underwent adjuvant postoperative irradiation what included 27 fractions of 2 Gy given over 4 weeks. A total of 5 out of 6 parotidectomies entailed a superficial lobectomy, while one was a total parotidectomy with composite resection of the masseter muscle in case of high-grade mucoepidermoid carcinoma. In four cases of superficial parotidectomy buccal branches were in intimate 7 relationship with the APG tumour and were sacrificed in order to achieve macroscopic tumour clearance. Apart from these patients in whom the facial nerve was partially sacrificed, two patients developed a facial palsy which fully recovered. Concomitant neck dissection was carried out in 3 of the 6 patients (50%), and comprised two selective neck dissections of level 2 and one selective neck dissection of levels 1 and 2.
Lymphadenectomies were electively performed in suspicious cases, though they yielded negative neck nodes. No postoperative complications were detected.
At the time of follow-up, five patients were disease-free, while one patient developed a locoregional recurrence with distant metastases of a high-grade mucoepidermoid carcinoma 8 months after initial surgical intervention and died 6 months later. At 5 years disease-free survival was 83.3%. Mean follow-up was 161 months (range, 14-253). Table 2) .
According to the literature, APG tumours most often present as an asimptomatic progressively enlarging cheek mass and usually occur in patients with a mean age ranging from 45 to 64.4 years at the time of presentation 1, 6, 7, 9 . In contrast, in this study group, patients were younger, with a mean age of 39 and 50% of patients presented with simptomatic lesions which included different head and neck complaints such as pain and numbness in mid-cheek area. Similar results were reported by Sun et al. 13 . Patients were evaluated through careful physical examination and additional diagnostic tools including fine-needle aspiration (FNA), computed tomography (CT) and magnetic resonance (MR).
Neck dissection was performed in cases of malignant or recurrent APG tumours. In this study, the incidence of APG tumours was 1.23% with a malignacy rate of 33.3% which is in range with prior reports 4, 5 . One patient with a malignant lesion of the APG died due to locoregional recurrence and distant disease from high grade mucoepidermoid carcinoma.
Similar biological behavior of mucoepidermoid carcinoma arising from APG tissue has been described before 14 .
After differential diagnosis, the second important question concerns the extent of surgical were found. Primarily due to oncological reasons, we doubt that the minimally invasive endoscopic resection is the best method of treatment for tumours of the APG. This opinion is supported by previous studies which reported reduced recurrence rates (less than 4%) associated with extended surgical techniques compared with the high incidence of recurrence (25-40%) resulting from enucleation among patients with pleomorphic adenoma of the parotid gland [17] [18] [19] . In addition, surgery of recurrent parotid gland tumours carries considerable risk of facial nerve injury which varies from 15 to 30% and the chance of recurrence is high ranging from 15 to 75% [20] [21] [22] [23] [24] [25] . Moreover, one year of follow-up is not a sufficient time interval for recurrence detection since recurrent benign parotid gland tumours occur 3 to 9 years after initial surgical treatment 21, [25] [26] [27] .
A clear weakness of this retrospective study is the small sample size. However, given the rarity of this entity, it's difficult to find larger series. Indications for elective neck dissection 11 in patients with malignant parotid and APGT tumours remains unclear. Further investigations are necessary in order to improve our better understanding of the subject.
In conclusion, APG tumours are extremely rare and represent a considerable diagnostic problem. Although nonsalivary diagnoses frequently occur in the buccal area, APG tumours should be considered in every differential diagnosis in patients presenting with a mid-cheek mass. In this study group, patients with APG tumours were younger than most reports in the literature state and half of them presented with a symptomatic mid-cheek mass unlike the typical asymptomatic cases from the literature. In order to establish the correct diagnosis, we advocate proper preoperative evaluation which includes a detailed physical examination, FNA and imaging techniques (CT and MR scans). Surgical resection remains the mainstay of treatment for both parotid and APG tumours. From oncosurgical, cosmetic, and functional standpoints, treatment by facelift parotidectomy approach or ''Sincision'' with concomitant superficial lobectomy is the recommended surgical approach, while a high-grade histological appearance requires total parotidectomy.
